Impact of the novel antidepressant agome
β
Maria-Antonia Quera-Salva; Patrick Lemoine; Christian Guilleminault
π
Article
π
2010
π
John Wiley and Sons
π
English
β 119 KB
π 1 views
## Abstract ## Background Disturbance of sleepβwake cycles is common in major depressive disorder (MDD), usually as insomnia, but also as hypersomnia or reduced daytime alertness. Agomelatine, an MT~1~ and MT~2~ receptor agonist and 5βHT~2C~ receptor antagonist, represents a novel approach in MDD,